Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.97 USD | +0.34% | -0.17% | -12.59% |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Financials (USD)
Sales 2024 * | 179M | Sales 2025 * | 202M | Capitalization | 261M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | - | EV / Sales 2024 * | 1.46 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.29 x |
P/E ratio 2024 * |
-14.4
x | P/E ratio 2025 * |
-448
x | Employees | 427 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.22% |
Latest transcript on AxoGen, Inc.
1 day | +0.34% | ||
1 week | -0.17% | ||
Current month | -6.86% | ||
1 month | -14.71% | ||
3 months | -43.68% | ||
6 months | +2.93% | ||
Current year | -12.59% |
Managers | Title | Age | Since |
---|---|---|---|
Karen Zaderej
CEO | Chief Executive Officer | 62 | 06-04-30 |
Nir Naor
DFI | Director of Finance/CFO | 50 | Dec. 05 |
Marc Began
CMP | Compliance Officer | 57 | 23-03-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Thomas
BRD | Director/Board Member | 68 | 20-09-29 |
Director/Board Member | 63 | 16-08-31 | |
John Johnson
BRD | Director/Board Member | 66 | 21-07-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 5.97 | +0.34% | 140,820 |
24-05-15 | 5.95 | +3.12% | 137,139 |
24-05-14 | 5.77 | -0.35% | 343,816 |
24-05-13 | 5.79 | +0.70% | 166,415 |
24-05-10 | 5.75 | -3.85% | 165,623 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.59% | 261M | |
+12.50% | 228B | |
+14.52% | 196B | |
+17.51% | 141B | |
+28.96% | 110B | |
+3.27% | 65.88B | |
+18.16% | 54.3B | |
+7.63% | 52.39B | |
+10.95% | 45.22B | |
+5.10% | 37.12B |
- Stock Market
- Equities
- AXGN Stock